The full content of Annals is available to subscribers

Subscribe/Learn More  >
Ideas and Opinions |

Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation?

Peter Zimetbaum, MD; and Mark E. Josephson, MD
[+] Article, Author, and Disclosure Information

From Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Peter Zimetbaum, MD, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Boston, MA 02215.

Current Author Addresses: Drs. Zimetbaum and Josephson: Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Boston, MA 02215.

Ann Intern Med. 2004;141(9):720-726. doi:10.7326/0003-4819-141-9-200411020-00015
Text Size: A A A

Recent studies have indicated that outcomes in patients with atrial fibrillation who are managed with rate control and anticoagulation are similar to those in patients who have maintenance of sinus rhythm. These studies did not include important groups of patients with atrial fibrillation in whom antiarrhythmic therapy may be appropriate. This perspective argues for the maintenance of sinus rhythm and for the use of antiarrhythmic therapy that includes medications, invasive procedures, and a combination of both in appropriate patients.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
The Dry Pipeline of Antiarrythmic Therapies
Posted on November 1, 2004
Amnon Schlegel
Univesity of California, San Francisco
Conflict of Interest: None Declared

To the Editor:

Zimetbaum and Josephson are confident that "new approaches to drug development and screening for risk for adverse events may ultimately reduce the toxicity of these agents (1)."

Unfortunately, this optimism has fallen on deaf ears in the pharmaceutical industry: the only "new" drugs to treat atrial fibrillation are dofetilide, ibutilide, and azimilide (2,3). These class III antiarrythmics, far from being bold breakthroughs in the management of atrial fibrillation, are "niche" players (2) whose long-term efficacy and toxicity are matters of speculation (3).

The remaining antiarrythmics the authors advocate for those who fail rate control, have contraindications to systemic anticoagulation, or who were otherwise excluded from the AFFIRM study based on age or comorbidites(4); have very high toxicities including lethal arrhythmias. Furthermore, their dosing is a matter of heated debate, and their monitoring is difficult and expensive. Large trials using the "hybrid" therapies they advocate should be organized to determine if the combination of expensive and marginally therapeutic drugs and ablative procedures are better than rate control (4,5).

References: 1. Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med. 2004;141:720-6

2. Sing BN, Sarma, JSM. What niche will newer class III antiarrythmic drugs occupy? Curr Cardiol Rep. 2001;3:314-23. [PMID: 11406090]

3. Naccarelli GV, Wolbrette DL, Bhatta L, Khan M, Hynes J, Samii S, Luck J. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol. 2003;9:215-22. [PMID: 14574034]

4. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al.. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. [PMID: 12466506]

5. Marshall DA, Levy AR, Vidaillet H, et al. Cost- Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation. Ann Intern Med. 2004; 141:653-661.

Conflict of Interest:

None declared

Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.